COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

6.44%

Decreased from previous period

Growth of 6.44% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

5.53%

Decreased from previous period

Cost growth of 5.53% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

10.34%

Decreased from previous period

Growth of 10.34% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

3.67%

Increased from previous period

Margin change of 3.67% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-15.82%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

2.61%

Decreased from previous period

Operating expenses change of 2.61% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

5.09%

Decreased from previous period

Total costs change of 5.09% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-15.38%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-14.91%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

32.32%

Increased from previous period

EBITDA change of 32.32% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

24.32%

Increased from previous period

Margin change of 24.32% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

35.65%

Increased from previous period

Income change of 35.65% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

27.45%

Increased from previous period

Margin change of 27.45% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-10.80%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

32.47%

Increased from previous period

Income change of 32.47% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

24.46%

Increased from previous period

Margin change of 24.46% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

27.04%

Increased from previous period

Tax expense change of 27.04% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

36.95%

Increased from previous period

Income change of 36.95% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

28.66%

Increased from previous period

Margin change of 28.66% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

-31.52%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-31.52%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

100.00%

Share count change of 100.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

100.00%

Diluted share change of 100.00% versus stable Healthcare. Walter Schloss would verify approach.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

6.44%

Decreased from previous period

Growth of 6.44% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

5.53%

Decreased from previous period

Cost growth of 5.53% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

10.34%

Decreased from previous period

Growth of 10.34% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

3.67%

Increased from previous period

Margin change of 3.67% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-15.82%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

2.61%

Decreased from previous period

Operating expenses change of 2.61% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

5.09%

Decreased from previous period

Total costs change of 5.09% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-15.38%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-14.91%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

32.32%

Increased from previous period

EBITDA change of 32.32% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

24.32%

Increased from previous period

Margin change of 24.32% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

35.65%

Increased from previous period

Income change of 35.65% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

27.45%

Increased from previous period

Margin change of 27.45% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-10.80%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

32.47%

Increased from previous period

Income change of 32.47% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

24.46%

Increased from previous period

Margin change of 24.46% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

27.04%

Increased from previous period

Tax expense change of 27.04% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

36.95%

Increased from previous period

Income change of 36.95% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

28.66%

Increased from previous period

Margin change of 28.66% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

-31.52%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-31.52%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

100.00%

Share count change of 100.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

100.00%

Diluted share change of 100.00% versus stable Healthcare. Walter Schloss would verify approach.

Select Chart Metric: